Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Arbutus HBV data 'could represent a turning point,' says Chardan » 12:12
09/15/20
09/15
12:12
09/15/20
12:12
ABUS

Arbutus Biopharma

$2.85 /

+0.23 (+8.78%)

Arbutus Biopharma this…

Arbutus Biopharma this morning announced "impressive" interim data from the Phase Ia/Ib clinical trial evaluating its lead asset, AB-729, as a treatment for chronic hepatitis B virus, Chardan analyst Keay Nakae tells investors in a research note. The data show an even greater knockdown of HBsAg compared to what was observed at 12 weeks for a single 60 mg dose, says the analyst. Nakae believes the positive results for AB-729 "could represent a turning point" for Arbutus and lead to a partnership. The analyst maintains a Buy rating on the shares with a $5 price target.

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.85 /

+0.23 (+8.78%)

ABUS Arbutus Biopharma
$2.85 /

+0.23 (+8.78%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$2.85 /

+0.23 (+8.78%)

ABUS Arbutus Biopharma
$2.85 /

+0.23 (+8.78%)

ABUS Arbutus Biopharma
$2.85 /

+0.23 (+8.78%)

Hot Stocks
Arbutus Biopharma announces AB-729 90 mg single-dose week 12 data in HBV » 07:49
09/15/20
09/15
07:49
09/15/20
07:49
ABUS

Arbutus Biopharma

$2.62 /

+0.245 (+10.32%)

Arbutus Biopharma reports…

Arbutus Biopharma reports continued positive data from an ongoing Phase 1a/1b clinical trial with AB-729, its proprietary GalNAc delivered RNAi compound. These new data demonstrate that in chronic HBV subjects, a single subcutaneous injection of 90 mg of AB-729 resulted in a mean HBsAg reduction of 1.23 log10 IU/mL at week 12. Arbutus expects to present initial results from its ongoing Phase 1a/1b clinical trial for the 60 mg multi-dose cohorts, the 90 mg single-dose cohort in HBV DNA positive subjects, as well as longer-term follow up of the 60 and 90 mg single-dose cohorts, at an upcoming scientific meeting later this year. In addition to the ongoing 60 mg multi-dose cohorts with subjects dosed at 4- and 8-weeks, the Company has also initiated 90 mg multi-dose cohorts with subjects dosed at 8- and 12-week intervals. AB-729-001 is an ongoing first-in-human clinical trial consisting of three parts: In Part 1, three cohorts of healthy subjects were randomized 4:2 to receive single-doses of AB-729 or placebo. In Part 2, non-cirrhotic, HBeAg positive or negative, chronic HBV subjects on a background of nucleoside therapy with HBV DNA below the limit of quantitation received single-doses of AB-729. An additional cohort in Part 2 included 90 mg single-dose of AB-729 in HBV DNA positive chronic HBV subjects. In Part 3, chronic HBV subjects, HBV DNA negative first and HBV DNA positive later, are receiving multi-doses of AB-729 for up to six months.

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.62 /

+0.245 (+10.32%)

ABUS Arbutus Biopharma
$2.62 /

+0.245 (+10.32%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$2.62 /

+0.245 (+10.32%)

ABUS Arbutus Biopharma
$2.62 /

+0.245 (+10.32%)

ABUS Arbutus Biopharma
$2.62 /

+0.245 (+10.32%)

Over a month ago
Syndicate
Arbutus Biopharma files $200M mixed securities shelf  16:08
08/28/20
08/28
16:08
08/28/20
16:08
ABUS

Arbutus Biopharma

$3.01 /

+0.1 (+3.44%)

 
ShowHide Related Items >><<
ABUS Arbutus Biopharma
$3.01 /

+0.1 (+3.44%)

ABUS Arbutus Biopharma
$3.01 /

+0.1 (+3.44%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$3.01 /

+0.1 (+3.44%)

ABUS Arbutus Biopharma
$3.01 /

+0.1 (+3.44%)

ABUS Arbutus Biopharma
$3.01 /

+0.1 (+3.44%)

Hot Stocks
Arbutus, Assembly Biosciences announce clinical collaboration agreement » 08:14
08/27/20
08/27
08:14
08/27/20
08:14
ABUS

Arbutus Biopharma

$2.94 /

-0.07 (-2.33%)

, ASMB

Assembly Biosciences

$21.06 /

-0.49 (-2.27%)

Assembly Biosciences…

Assembly Biosciences (ASMB) and Arbutus Biopharma Corporation (ABUS) announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly's lead hepatitis B virus core inhibitor candidate ABI-H0731 in combination with Arbutus' proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor therapy for the treatment of patients with chronic HBV infection. A randomized, multi-center, open-label Phase 2 clinical trial will explore the safety, pharmacokinetics, and antiviral activity of the triple combination of HBV core inhibitor ABI-H0731, RNAi therapeutic AB-729 and an NrtI compared to the double combinations of ABI-H0731 with an NrtI and AB-729 with an NrtI. This clinical trial is projected to initiate in the first half of 2021 and enroll approximately 60 virologically-suppressed patients with HBeAg negative or positive chronic HBV infection. Patients will be dosed for 48 weeks, with a 24 week follow-up period. As part of the collaboration, the companies may add cohorts in the future, to evaluate other patient populations and/or combinations.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$21.06 /

-0.49 (-2.27%)

ABUS Arbutus Biopharma
$2.94 /

-0.07 (-2.33%)

ABUS Arbutus Biopharma
$2.94 /

-0.07 (-2.33%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ASMB Assembly Biosciences
$21.06 /

-0.49 (-2.27%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
ASMB Assembly Biosciences
$21.06 /

-0.49 (-2.27%)

ABUS Arbutus Biopharma
$2.94 /

-0.07 (-2.33%)

  • 12
    Dec
ABUS Arbutus Biopharma
$2.94 /

-0.07 (-2.33%)

ABUS Arbutus Biopharma
$2.94 /

-0.07 (-2.33%)

Options
Largest borrow rate increases among liquid names » 08:45
08/18/20
08/18
08:45
08/18/20
08:45
AYRO

AYRO

$3.60 /

-0.155 (-4.13%)

, CVM

CEL-SCI

$12.43 /

-0.3 (-2.36%)

, GPL

Great Panther Mining

$1.01 /

+0.098 (+10.75%)

, BLDP

Ballard Power

$15.55 /

+1.195 (+8.33%)

, SLG

SL Green Realty

$46.86 /

-0.52 (-1.10%)

, EWG

iShares MSCI Germany

$29.93 /

+0.275 (+0.93%)

, CNK

Cinemark

$12.79 /

+0.12 (+0.95%)

, NIO

NIO Inc.

$14.05 /

+0.935 (+7.13%)

, ABUS

Arbutus Biopharma

$3.48 /

+0.02 (+0.58%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: AYRO (AYRO) 97.06% +0.69, Cel Sci (CVM) 61.90% +0.59, Great Panther Silver (GPL) 19.19% +0.58, Ballard Power (BLDP) 5.53% +0.25, SL Green Realty (SLG) 0.36% +0.11, ProShares UltraPro Short Dow 30 (SDOW) 0.47% +0.07, iShares Germany (EWG) 2.22% +0.06, Cinemark (CNK) 0.34% +0.06, NIO (NIO) 0.71% +0.05, and Arbutus Biopharma (ABUS) 4.68% +0.05.

ShowHide Related Items >><<
SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

GPL Great Panther Mining
$1.01 /

+0.098 (+10.75%)

CVM CEL-SCI
$12.43 /

-0.3 (-2.36%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

BLDP Ballard Power
$15.55 /

+1.195 (+8.33%)

AYRO AYRO
$3.60 /

-0.155 (-4.13%)

ABUS Arbutus Biopharma
$3.48 /

+0.02 (+0.58%)

AYRO AYRO
$3.60 /

-0.155 (-4.13%)

CVM CEL-SCI
$12.43 /

-0.3 (-2.36%)

05/14/20 H.C. Wainwright
CEL-SCI price target raised to $23 from $18 at H.C. Wainwright
01/13/20 H.C. Wainwright
CEL-SCI initiated with a Buy at H.C. Wainwright
GPL Great Panther Mining
$1.01 /

+0.098 (+10.75%)

07/10/20 Alliance Global Partners
Great Panther price target raised to 80c from 65c at Alliance Global
07/10/20 H.C. Wainwright
Great Panther Mining price target raised to $2 from $1.75 at H.C. Wainwright
05/11/20 Noble Capital
Great Panther Silver downgraded to Market Perform from Outperform at Noble Capital
01/15/20 Noble Capital
Great Panther Silver upgraded to Outperform from Market Perform at Noble Capital
BLDP Ballard Power
$15.55 /

+1.195 (+8.33%)

08/17/20 TD Securities
Ballard Power upgraded to Speculative Buy from Hold at TD Securities
08/17/20 TD Securities
Ballard Power upgraded to Speculative Buy from Hold at TD Securities
08/07/20 Lake Street
Ballard Power price target raised to $20 from $13 at Lake Street
07/13/20 Roth Capital
Ballard Power price target raised to $25 from $20 at Roth Capital
SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

07/27/20 Truist
SL Green Realty price target lowered to $75 from $80 at SunTrust
07/20/20 Deutsche Bank
SL Green downgraded to Hold on 'strained fundamentals' at Deutsche Bank
07/20/20 Deutsche Bank
SL Green Realty downgraded to Hold from Buy at Deutsche Bank
05/28/20 Morgan Stanley
Morgan Stanley downgrades Vornado, upgrades SL Green in NYC Office REIT shuffle
EWG iShares MSCI Germany
$29.93 /

+0.275 (+0.93%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

08/05/20 JPMorgan
Cinemark price target lowered to $19 from $23 at JPMorgan
07/29/20 Wedbush
Cinemark price target lowered to $15 from $20 at Wedbush
07/15/20 Goldman Sachs
Cinemark initiated with a Neutral at Goldman Sachs
07/13/20 MKM Partners
MKM Partners lowers price targets in Cinema sector
NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

08/12/20 Piper Sandler
NIO Inc. price target raised to $14 from $4 at Piper Sandler
07/21/20 CICC
NIO Inc. upgraded to Outperform from Neutral at CICC
07/17/20
Fly Intel: Top five analyst downgrades
07/17/20 Goldman Sachs
NIO Inc. downgraded to Sell from Neutral at Goldman Sachs
ABUS Arbutus Biopharma
$3.48 /

+0.02 (+0.58%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

GPL Great Panther Mining
$1.01 /

+0.098 (+10.75%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

BLDP Ballard Power
$15.55 /

+1.195 (+8.33%)

ABUS Arbutus Biopharma
$3.48 /

+0.02 (+0.58%)

  • 11
    Jun
  • 24
    Dec
SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

BLDP Ballard Power
$15.55 /

+1.195 (+8.33%)

SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

GPL Great Panther Mining
$1.01 /

+0.098 (+10.75%)

CVM CEL-SCI
$12.43 /

-0.3 (-2.36%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

ABUS Arbutus Biopharma
$3.48 /

+0.02 (+0.58%)

SLG SL Green Realty
$46.86 /

-0.52 (-1.10%)

NIO NIO Inc.
$14.05 /

+0.935 (+7.13%)

GPL Great Panther Mining
$1.01 /

+0.098 (+10.75%)

EWG iShares MSCI Germany
$29.93 /

+0.275 (+0.93%)

CVM CEL-SCI
$12.43 /

-0.3 (-2.36%)

CNK Cinemark
$12.79 /

+0.12 (+0.95%)

BLDP Ballard Power
$15.55 /

+1.195 (+8.33%)

AYRO AYRO
$3.60 /

-0.155 (-4.13%)

Conference/Events
Wedbush to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
ABUS

Arbutus Biopharma

$3.44 /

-0.21 (-5.75%)

, BHVN

Biohaven Pharmaceutical

$59.86 /

-2.09 (-3.37%)

, IDRA

Idera Pharmaceuticals

$2.17 /

-0.04 (-1.81%)

, ALNA

Allena Pharmaceuticals

$1.40 /

-0.08 (-5.41%)

, CLSD

Clearside Biomedical

$1.72 /

-0.07 (-3.91%)

, VIE

Viela Bio

$36.02 /

-1.94 (-5.11%)

, AQST

Aquestive Therapeutics

$6.60 /

-0.35 (-5.04%)

, LQDA

Liquidia Technologies

$5.40 /

-0.48 (-8.16%)

, UTHR

United Therapeutics

$109.46 /

-1.49 (-1.34%)

, NTLA

Intellia Therapeutics

$19.53 /

-0.89 (-4.36%)

, KURA

Kura Oncology

$20.66 /

-0.67 (-3.14%)

, NBRV

Nabriva Therapeutics

$0.72 /

-0.0096 (-1.32%)

, MYOK

MyoKardia

$101.01 /

-3.86 (-3.68%)

, MRUS

Merus

$12.99 /

-0.23 (-1.74%)

, RCUS

Arcus Biosciences

$22.99 /

+0.03 (+0.13%)

, RARE

Ultragenyx

$82.73 /

-2.34 (-2.75%)

, MRSN

Mersana Therapeutics

$18.52 /

-1.52 (-7.58%)

, KALA

Kala Pharmaceuticals

$8.94 /

-0.3 (-3.25%)

, FENC

Fennec

$6.66 /

-3.48 (-34.32%)

, FPRX

Five Prime

$4.76 /

-0.4 (-7.75%)

, STRO

Sutro Biopharma

$8.49 /

+0.03 (+0.35%)

, SURF

Surface Oncology

$5.92 /

-0.04 (-0.67%)

, SWTX

SpringsWorks Therapeutics

$44.36 /

-1.1 (-2.42%)

, ISEE

Iveric bio

$4.39 /

-0.145 (-3.20%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$12.99 /

-0.23 (-1.74%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$6.66 /

-3.48 (-34.32%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

Hot Stocks
Arbutus Biopharma higher after Moderna discusses patent uncertainty » 12:09
08/11/20
08/11
12:09
08/11/20
12:09
ABUS

Arbutus Biopharma

$3.61 /

-0.04 (-1.10%)

, MRNA

Moderna

$69.85 /

-2.18 (-3.03%)

Moderna (MRNA) said in a…

Moderna (MRNA) said in a regulatory filing that the company "cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273." Previously, on July 24, Moderna released a statement that read in part: "The recently issued Patent Trial and Appeal Board ruling on the 8,058,069 patent relates to Moderna's challenge to certain legacy patents held by Arbutus (ABUS), commenced well before the development of mRNA-1273. These actions were taken by Moderna in response to the longstanding aggressive posture taken by Arbutus and its predecessor company against many developers of nucleic acid-based therapeutics." In early afternoon trading, Arbutus shares are up 17c, or 4.6%, to $3.83.

ShowHide Related Items >><<
MRNA Moderna
$69.85 /

-2.18 (-3.03%)

ABUS Arbutus Biopharma
$3.61 /

-0.04 (-1.10%)

ABUS Arbutus Biopharma
$3.61 /

-0.04 (-1.10%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
MRNA Moderna
$69.85 /

-2.18 (-3.03%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
MRNA Moderna
$69.85 /

-2.18 (-3.03%)

ABUS Arbutus Biopharma
$3.61 /

-0.04 (-1.10%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$69.85 /

-2.18 (-3.03%)

MRNA Moderna
$69.85 /

-2.18 (-3.03%)

ABUS Arbutus Biopharma
$3.61 /

-0.04 (-1.10%)

MRNA Moderna
$69.85 /

-2.18 (-3.03%)

Conference/Events
Wedbush to hold a virtual conference » 08:35
08/11/20
08/11
08:35
08/11/20
08:35
ABUS

Arbutus Biopharma

$3.65 /

-0.13 (-3.44%)

, BHVN

Biohaven Pharmaceutical

$61.95 /

-5.72 (-8.45%)

, IDRA

Idera Pharmaceuticals

$2.21 /

+0.12 (+5.74%)

, ALNA

Allena Pharmaceuticals

$1.48 /

-0.015 (-1.00%)

, CLSD

Clearside Biomedical

$1.79 /

+0.035 (+1.99%)

, VIE

Viela Bio

$37.96 /

+0.79 (+2.13%)

, AQST

Aquestive Therapeutics

$6.95 /

+0.66 (+10.49%)

, LQDA

Liquidia Technologies

$5.88 /

-0.35 (-5.62%)

, UTHR

United Therapeutics

$110.95 /

-1.84 (-1.63%)

, NTLA

Intellia Therapeutics

$20.42 /

+0.63 (+3.18%)

, KURA

Kura Oncology

$21.33 /

+0.95 (+4.66%)

, NBRV

Nabriva Therapeutics

$0.73 /

-0.005 (-0.68%)

, MYOK

MyoKardia

$104.87 /

+1.36 (+1.31%)

, MRUS

Merus

$13.22 /

+0.02 (+0.15%)

, RCUS

Arcus Biosciences

$22.96 /

+1.18 (+5.42%)

, RARE

Ultragenyx

$85.07 /

+0.37 (+0.44%)

, MRSN

Mersana Therapeutics

$20.04 /

-0.23 (-1.13%)

, KALA

Kala Pharmaceuticals

$9.24 /

+0.35 (+3.94%)

, FENC

Fennec

$10.14 /

+1.14 (+12.67%)

, FPRX

Five Prime

$5.16 /

-0.46 (-8.19%)

, STRO

Sutro Biopharma

$8.46 /

-0.05 (-0.59%)

, SURF

Surface Oncology

$5.96 /

-0.01 (-0.17%)

, SWTX

SpringsWorks Therapeutics

$45.46 /

+0.31 (+0.69%)

, ISEE

Iveric bio

$4.53 /

+0.11 (+2.49%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$13.22 /

+0.02 (+0.15%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$10.14 /

+1.14 (+12.67%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

On The Fly
Fly Intel: Pre-market Movers » 09:04
08/07/20
08/07
09:04
08/07/20
09:04
BIIB

Biogen

$277.44 /

+1.3 (+0.47%)

, RKT

Rocket Companies

$21.62 /

+ (+0.00%)

, TMUS

T-Mobile

$108.04 /

+0.2 (+0.19%)

, DISH

Dish

$34.30 /

+0.23 (+0.68%)

, TILE

Interface

$8.14 /

-0.11 (-1.33%)

, CSIQ

Canadian Solar

$23.62 /

-0.16 (-0.67%)

, SMLP

Summit Midstream

$0.93 /

+0.0622 (+7.20%)

, ROAD

Construction Partners

$18.60 /

+0.15 (+0.81%)

, TRIP

TripAdvisor

$21.62 /

+0.52 (+2.46%)

, ZG

Zillow

$71.65 /

+1.13 (+1.60%)

, BKNG

Booking Holdings

$1,749.80 /

+24.33 (+1.41%)

, CNTY

Century Casinos

$4.80 /

+0.56 (+13.21%)

, NOG

Northern Oil and Gas

$0.86 /

+0.0201 (+2.39%)

, CCO

Clear Channel Outdoor

$0.95 /

+0.0176 (+1.88%)

, SABR

Sabre

$8.29 /

+0.105 (+1.28%)

, ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

, ILMN

Illumina

$400.55 /

-0.29 (-0.07%)

, AQUA

Evoqua Water

$21.70 /

+1.1 (+5.34%)

Check out this morning's…

ShowHide Related Items >><<
ZG Zillow
$71.65 /

+1.13 (+1.60%)

TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

TILE Interface
$8.14 /

-0.11 (-1.33%)

SMLP Summit Midstream
$0.93 /

+0.0622 (+7.20%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

ROAD Construction Partners
$18.60 /

+0.15 (+0.81%)

NOG Northern Oil and Gas
$0.86 /

+0.0201 (+2.39%)

ILMN Illumina
$400.55 /

-0.29 (-0.07%)

DISH Dish
$34.30 /

+0.23 (+0.68%)

CSIQ Canadian Solar
$23.62 /

-0.16 (-0.67%)

CNTY Century Casinos
$4.80 /

+0.56 (+13.21%)

CCO Clear Channel Outdoor
$0.95 /

+0.0176 (+1.88%)

BKNG Booking Holdings
$1,749.80 /

+24.33 (+1.41%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

AQUA Evoqua Water
$21.70 /

+1.1 (+5.34%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

08/07/20 Stifel
Biogen jump of 10% on priority review for aducanumab not a surprise to Stifel
08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
07/27/20
Fly Intel: Top five analyst upgrades
RKT Rocket Companies
$21.62 /

+ (+0.00%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

08/07/20 JPMorgan
T-Mobile price target raised to $140 from $110 at JPMorgan
08/07/20 Goldman Sachs
T-Mobile price target raised to $135 from $123 at Goldman Sachs
07/29/20
Fly Intel: Top five analyst initiations
07/29/20
Fly Intel: Top five analyst downgrades
DISH Dish
$34.30 /

+0.23 (+0.68%)

07/20/20 Credit Suisse
F5 Networks price target raised to $170 from $151 at Credit Suisse
07/16/20 JPMorgan
Dish resumed with a Neutral from Overweight at JPMorgan
06/12/20 Truist
Dish price target raised to $30 from $23 at SunTrust
06/12/20 Deutsche Bank
Deutsche Bank still believes Dish acquisition of Boost will close
TILE Interface
$8.14 /

-0.11 (-1.33%)

05/11/20 Nomura Instinet
Interface price target raised to $16 from $13 at Nomura Instinet
02/27/20 Raymond James
Interface's valuation, guidance 'more reasonable,' says Raymond James
02/27/20 Raymond James
Interface upgraded to Market Perform from Underperform at Raymond James
01/22/20 Nomura Instinet
Interface named top Building pick into Q4 earnings at Nomura Instinet
CSIQ Canadian Solar
$23.62 /

-0.16 (-0.67%)

07/20/20 Roth Capital
Roth boosts Daqo target to $120 after polysilicon facility explosion reports
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
08/16/19 Roth Capital
Canadian Solar price target raised to $32 from $27 at Roth Capital
SMLP Summit Midstream
$0.93 /

+0.0622 (+7.20%)

01/07/20 Wells Fargo
Summit Midstream downgraded to Underweight at Wells Fargo
01/07/20 Wells Fargo
Summit Midstream downgraded to Underweight from Equal Weight at Wells Fargo
08/19/19 RBC Capital
Summit Midstream price target lowered to $6 from $9 at RBC Capital
ROAD Construction Partners
$18.60 /

+0.15 (+0.81%)

05/13/20 Imperial Capital
Construction Partners price target lowered to $16 from $20 at Imperial Capital
05/12/20 Raymond James
Construction Partners downgraded to Outperform from Strong Buy at Raymond James
05/12/20 Raymond James
Construction Partners downgraded to Outperform from Strong Buy at Raymond James
04/09/20 DA Davidson
Construction Partners downgraded to Neutral from Buy at DA Davidson
TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

07/29/20 Jefferies
Booking Holdings price target raised to $1,600 from $1,300 at Jefferies
06/23/20 RBC Capital
TripAdvisor's Q2 update implies sequential improvement, says RBC Capital
06/10/20 BTIG
TripAdvisor initiated with a Neutral at BTIG
05/11/20 Credit Suisse
TripAdvisor price target lowered to $22 from $28 at Credit Suisse
ZG Zillow
$71.65 /

+1.13 (+1.60%)

08/07/20 Craig-Hallum
Zillow price target raised to $90 from $67 at Craig-Hallum
08/07/20 Morgan Stanley
Zillow price target raised to $75 from $64 at Morgan Stanley
08/07/20 DA Davidson
Zillow price target raised to $94 from $65 at DA Davidson
08/07/20 BTIG
Zillow price target raised to $99 from $79 at BTIG
BKNG Booking Holdings
$1,749.80 /

+24.33 (+1.41%)

08/07/20 Credit Suisse
Booking Holdings price target raised to $2,150 from $2,060 at Credit Suisse
08/07/20 Mizuho
Booking Holdings price target raised to $2,020 from $1,700 at Mizuho
08/05/20 Deutsche Bank
Booking Holdings price target raised to $2,000 from $1,625 at Deutsche Bank
CNTY Century Casinos
$4.80 /

+0.56 (+13.21%)

02/25/20 Roth Capital
Roth sees upside in Century Casinos shares after co-CEO meetings
10/21/19 Union Gaming
Century Casinos upgraded to Buy from Hold at Union Gaming
NOG Northern Oil and Gas
$0.86 /

+0.0201 (+2.39%)

07/27/20 Seaport Global
Northern Oil and Gas initiated with a Buy at Seaport Global
07/01/20 Truist
Northern Oil and Gas upgraded to Buy from Hold at SunTrust
07/01/20 Truist
Northern Oil and Gas upgraded to Buy from Hold at SunTrust
07/01/20 Truist
Northern Oil and Gas upgraded to Buy from Hold at SunTrust
CCO Clear Channel Outdoor
$0.95 /

+0.0176 (+1.88%)

06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 Citi
Clear Channel Outdoor upgraded to Buy from Neutral at Citi
06/16/20 Cowen
Clear Channel Outdoor price target raised to $2.20 from $1.50 at Cowen
04/01/20 Barrington
Clear Channel Outdoor downgraded to Market Perform from Outperform at Barrington
SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ILMN Illumina
$400.55 /

-0.29 (-0.07%)

08/07/20 Evercore ISI
Illumina downgraded to Underperform from In Line at Evercore ISI
08/07/20 Piper Sandler
Illumina downgraded to Neutral from Overweight at Piper Sandler
07/07/20 Guggenheim
Illumina downgraded to Neutral following 81% rise off lows at Guggenheim
07/07/20 Guggenheim
Illumina downgraded to Neutral from Buy at Guggenheim
AQUA Evoqua Water
$21.70 /

+1.1 (+5.34%)

04/08/20 Goldman Sachs
Evoqua Water upgraded to Buy from Neutral at Goldman Sachs
03/23/20 Stifel
Evoqua Water debt covenant issues unlikely, says Stifel
02/05/20 RBC Capital
Evoqua Water price target raised to $26 from $22 at RBC Capital
01/15/20 Jefferies
Evoqua Water initiated with a Hold at Jefferies
ZG Zillow
$71.65 /

+1.13 (+1.60%)

TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

TILE Interface
$8.14 /

-0.11 (-1.33%)

SMLP Summit Midstream
$0.93 /

+0.0622 (+7.20%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

ROAD Construction Partners
$18.60 /

+0.15 (+0.81%)

NOG Northern Oil and Gas
$0.86 /

+0.0201 (+2.39%)

ILMN Illumina
$400.55 /

-0.29 (-0.07%)

DISH Dish
$34.30 /

+0.23 (+0.68%)

CSIQ Canadian Solar
$23.62 /

-0.16 (-0.67%)

CNTY Century Casinos
$4.80 /

+0.56 (+13.21%)

CCO Clear Channel Outdoor
$0.95 /

+0.0176 (+1.88%)

BKNG Booking Holdings
$1,749.80 /

+24.33 (+1.41%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

AQUA Evoqua Water
$21.70 /

+1.1 (+5.34%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

  • 07
    Aug
  • 06
    Aug
  • 24
    Jun
  • 11
    Jun
  • 06
    Mar
  • 18
    Sep
TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

RKT Rocket Companies
$21.62 /

+ (+0.00%)

DISH Dish
$34.30 /

+0.23 (+0.68%)

BKNG Booking Holdings
$1,749.80 /

+24.33 (+1.41%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

ZG Zillow
$71.65 /

+1.13 (+1.60%)

TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

SMLP Summit Midstream
$0.93 /

+0.0622 (+7.20%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

RKT Rocket Companies
$21.62 /

+ (+0.00%)

NOG Northern Oil and Gas
$0.86 /

+0.0201 (+2.39%)

ILMN Illumina
$400.55 /

-0.29 (-0.07%)

DISH Dish
$34.30 /

+0.23 (+0.68%)

CSIQ Canadian Solar
$23.62 /

-0.16 (-0.67%)

CNTY Century Casinos
$4.80 /

+0.56 (+13.21%)

CCO Clear Channel Outdoor
$0.95 /

+0.0176 (+1.88%)

BKNG Booking Holdings
$1,749.80 /

+24.33 (+1.41%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

AQUA Evoqua Water
$21.70 /

+1.1 (+5.34%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

TRIP TripAdvisor
$21.62 /

+0.52 (+2.46%)

TMUS T-Mobile
$108.04 /

+0.2 (+0.19%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

ILMN Illumina
$400.55 /

-0.29 (-0.07%)

DISH Dish
$34.30 /

+0.23 (+0.68%)

CSIQ Canadian Solar
$23.62 /

-0.16 (-0.67%)

BIIB Biogen
$277.44 /

+1.3 (+0.47%)

Hot Stocks
Arbutus cannot predict negative impacts from COVID-19 on plans, timelines » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In December 2019 an…

In December 2019 an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, and prohibitions in certain countries on enrolling subjects in new clinical trials. While we have been able to progress with our clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will negatively impact our plans and timelines in the future.

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.